文献速递肝病

地中海饮食较低脂饮食的心代谢获益可能由降低肝脏脂肪含量介导

The beneficial effects of Mediterranean diet over low-fat diet may be mediated by decreasing hepatic fat content.
PubMed 文献 · J Hepatol · 2019-05-08

在18个月减重试验中,278例腹部肥胖/血脂异常者随机接受低脂或地中海/低碳水化合物饮食,伴或不伴中等强度体力活动。肝脏脂肪含量在6个月和18个月显著下降,且地中海/低碳水化合物饮食较低脂饮食更有效降低肝脏脂肪含量,独立于内脏脂肪变化。地中海/低碳水化合物饮食对心代谢参数的改善在控制肝脏脂肪含量变化后明显减弱,提示其获益更多由肝脏脂肪降低介导。

要点

  • 地中海/低碳水化合物饮食较低脂饮食更有效降低肝脏脂肪含量(p=0.036),独立于内脏脂肪变化。
  • 肝脏脂肪含量降低独立于内脏脂肪减少,与γ-谷氨酰转移酶、丙氨酸氨基转移酶、chemerin及糖化血红蛋白下降相关(p<0.05)。
  • 地中海/低碳水化合物饮食对心代谢参数的改善在控制肝脏脂肪含量变化后明显减弱,提示肝脏脂肪降低是主要介导因素。

核心结论

  • 肝脏脂肪含量百分比可通过饮食诱导的中度减重显著降低,且地中海/低碳水化合物饮食较低脂饮食更有效,独立于内脏脂肪变化。
  • 地中海/低碳水化合物饮食对特定心代谢参数的有利效应似乎更多由肝脏脂肪含量百分比降低而非内脏脂肪减少所介导。

研究设计与样本

  • 18个月减重试验(CENTRAL),278例腹部肥胖/血脂异常参与者随机分配至低脂饮食或地中海/低碳水化合物饮食(+28克核桃/天),伴或不伴中等强度体力活动。
  • 肝脏脂肪含量和腹部脂肪沉积采用磁共振成像在基线、6个月(亚组,n=158)和18个月时测量。

主要发现

  • 278例参与者平均肝脏脂肪含量为10.2%(范围0.01%-50.4%),保留率为86.3%。
  • 肝脏脂肪含量百分比在6个月后绝对下降6.6%(相对下降41%),18个月后绝对下降4.0%(相对下降29%),与基线相比p<0.001。
  • 肝脏脂肪含量降低与内脏脂肪减少相关,且独立于体重减轻。
  • 控制内脏脂肪减少后,肝脏脂肪含量百分比下降仍独立与血清γ-谷氨酰转移酶、丙氨酸氨基转移酶、循环chemerin及糖化血红蛋白降低相关(p<0.05)。
  • 肝脏脂肪含量降低在体力活动组间相似,但地中海/低碳水化合物饮食较低脂饮食诱导更大的肝脏脂肪含量百分比下降(p=0.036)和更大的心代谢风险参数改善(p<0.05),即使控制内脏脂肪变化后仍如此;然而控制肝脏脂肪含量变化后,地中海/低碳水化合物饮食诱导的更大心代谢风险参数改善均明显减弱。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIM: It is unclear if a reduction in hepatic fat content (HFC) is a major mediator of the cardiometabolic benefit of lifestyle intervention, and whether it has prognostic significance beyond the loss of visceral adipose tissue (VAT). In the present sub-study, we hypothesized that HFC loss in response to dietary interventions induces specific beneficial effects independently of VAT changes. METHODS: In an 18-month weight-loss trial, 278 participants with abdominal obesity/dyslipidemia were randomized to low-fat (LF) or Mediterranean/low-carbohydrate (MED/LC + 28 g walnuts/day) diets with/without moderate physical activity. HFC and abdominal fat-depots were measured using magnetic resonance imaging at baseline, after 6 (sub-study, n = 158) and 18 months. RESULTS: Of 278 participants (mean HFC 10.2% [range: 0.01%-50.4%]), the retention rate was 86.3%. The %HFC substantially decreased after 6 months (-6.6% absolute units [-41% relatively]) and 18 months (-4.0% absolute units [-29% relatively]; p <0.001 vs. baseline). Reductions of HFC were associated with decreases in VAT beyond weight loss. After controlling for VAT loss, decreased %HFC remained independently associated with reductions in serum gamma glutamyltransferase and alanine aminotransferase, circulating chemerin, and glycated hemoglobin (p <0.05). While the reduction in HFC was similar between physical activity groups, MED/LC induced a greater %HFC decrease (p = 0.036) and greater improvements in cardiometabolic risk parameters (p <0.05) than the LF diet, even after controlling for VAT changes. Yet, the greater improvements in cardiometabolic risk parameters induced by MED/LC were all markedly attenuated when controlling for HFC changes. CONCLUSIONS: %HFC is substantially reduced by diet-induced moderate weight loss and is more effectively reduced by the MED/LC diet than the LF diet, independently of VAT changes. The beneficial effects of the MED/LC diet on specific cardiometabolic parameters appear to be mediated more by decreases in %HFC than VAT loss. LAY SUMMARY: High hepatic fat content is associated with metabolic syndrome, type 2 diabetes mellitus, and coronary heart disease. In the CENTRAL 18-month intervention trial, a Mediterranean/low-carbohydrate diet induced a greater decrease in hepatic fat content than a low-fat diet, conferring beneficial health effects that were beyond the favorable effects of visceral fat loss. ClinicalTrials.gov Identifier: NCT01530724.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Gepner Y, Shelef I, Komy O, et al. The beneficial effects of Mediterranean diet over low-fat diet may be mediated by decreasing hepatic fat content. J Hepatol. 2019. PMID: 31075323. doi:10.1016/j.jhep.2019.04.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。